Literature DB >> 32281110

Distinct characteristics of COVID-19 patients with initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2.

Jin-Jin Zhang1, Yi-Yuan Cao2, Xiang Dong1, Bin-Chen Wang2, Mei-Yan Liao2, Jun Lin3, You-Qin Yan4, Cezmi A Akdis5, Ya-Dong Gao1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32281110      PMCID: PMC7262033          DOI: 10.1111/all.14316

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


× No keyword cloud information.
To the Editor, Since the coronavirus disease 2019 (COVID‐19) caused by SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) first emerged in Wuhan, China, in December 2019, the outbreak of COVID‐19 epidemic has become an increasingly serious global health concern. Currently, over 150 countries have reported COVID‐19 cases, and the situation has progressed to a pandemic associated with substantial morbidity and mortality. At present, rRT‐PCR (real‐time reverse transcription–polymerase chain reaction) assay is the most common and only direct method of SARS‐CoV‐2 detection for the diagnosis of COVID‐19. However, false‐negative results due to laboratory errors or improper collection of the specimens may inevitably lead to an important percentage of undiagnosed COVID‐19 patients. Some patients with suspected COVID‐19 have initial negative result of the rRT‐PCR test , or low viral concentration of SARS‐CoV‐2 at the sampling site in the early stages of the disease. This study aims to compare the clinical and laboratory characteristics of eventually confirmed COVID‐19 patients with initial positive and negative SARS‐CoV‐2 nucleic acid test results. The present study retrospectively reports 290 laboratory‐confirmed COVID‐19 patients hospitalized from December 29, 2019, to February 16, 2020. According to initial rRT‐PCR results, patients were divided into initial positive and negative groups. All rRT‐PCR assays were performed with the same kit (Shanghai bio‐germ Medical Technology Co Ltd). Electronic medical records, including patients’ demographics, clinical manifestation, comorbidities, laboratory results, and radiological materials on admission were collected and analyzed. The clinical outcomes of each patient were reviewed and analyzed on the final follow‐up (February 28, 2020) including disease severity, complications, and co‐infection status with other pathogens during hospitalization. This study was approved by the Zhongnan Hospital of Wuhan University institutional ethics board (No.2020015 and No. 2020028). Additional details on the methods are reported in the Supporting Information. Of the 290 patients involved in this study, an initial rRT‐PCR test was positive for SARS‐CoV‐2 by 249 (85.9%) patients and negative by 41 (14.1%) patients. Among the 41 patients with an initial negative result, 21 tested positive at the second rRT‐PCR test and 13 of them became positive at the third test. The cumulative positive ratio of rRT‐PCR assay of these 41 patients from the 2nd time to the 5th time of the test gradually increased from 51.2% (21/41) to 82.9% (34/41), 92.7% (38/41), and 97.6% (40/41) (Figure 1A), and the rRT‐PCR‐positive ratio of all 290 patients by the 5th test was 99.7% (289/290) (Figure 1B).
Figure 1

Number of patients testing positive for SARS‐CoV‐2 and the cumulative positive ratio at different rRT‐PCR tests. A, Changes in the outcome of the rRT‐PCR test of patients, from negative to positive, after consecutive assays. Of the 41 patients with an initial negative result, 21, 13, 4, 2, and 1 patients were tested positive at the 2nd, 3rd, 4th, 5th, and 6th rRT‐PCR assays, respectively. The cumulative positive rRT‐PCR assay ratio from the second to the fifth test increased from 51.2% (21/41) to 97.6% (40/41). B, Number and percentage of positive results within the total patient population. The cumulative positive ratio of all 290 patients from the first to the fifth test increased from 85.9% (249/290) to 99.7% (289/290). rRT‐PCR, real‐time reverse transcription–polymerase chain reaction

Number of patients testing positive for SARS‐CoV‐2 and the cumulative positive ratio at different rRT‐PCR tests. A, Changes in the outcome of the rRT‐PCR test of patients, from negative to positive, after consecutive assays. Of the 41 patients with an initial negative result, 21, 13, 4, 2, and 1 patients were tested positive at the 2nd, 3rd, 4th, 5th, and 6th rRT‐PCR assays, respectively. The cumulative positive rRT‐PCR assay ratio from the second to the fifth test increased from 51.2% (21/41) to 97.6% (40/41). B, Number and percentage of positive results within the total patient population. The cumulative positive ratio of all 290 patients from the first to the fifth test increased from 85.9% (249/290) to 99.7% (289/290). rRT‐PCR, real‐time reverse transcription–polymerase chain reaction The median age of the patients was 57 years (range, 22‐88 years), and 184 (63.5%) were aged over 50 years (Table 1). Of the 290 patients, 155 (53.4%) patients were male, but the majority [25 (61%)] of the patients with initial negative rRT‐PCR results were female. Of the 89 (30.7%) patients with surgery history, the proportion of patients with an initial positive rRT‐PCR result was significantly higher than that of patients with an initial negative rRT‐PCR result (32.9% vs 17.1%, P = .041).
Table 1

Demographics and partial clinical data of patients with COVID‐19

 All Patients (n = 290)Initial result of SARS‐CoV‐2 rRT‐PCR test
Positive (n = 249)Negative (n = 41) P value
Age—median (range)57 (22‐88)57 (22‐88)51 (22‐79).089
Age groups ‐No. (%)
<30 y16 (5.5)11 (4.4)5 (12.2).165
30‐49 y90 (31.0)76 (30.5)14 (34.1)
50‐69 y120 (41.4)107 (43)13 (31.7)
≥70 y64 (22.1)55 (22.1)9 (22.0)
Sex—No. (%)
Female135 (46.6)110 (44.2)25 (61.0).062
Male155 (53.4)139 (55.8)16 (39.0)
Exposure History—No. (%)
Yes83 (28.6)74 (29.7)9 (22.0).308
No207 (71.4)175 (70.3)32 (78.0)
Comorbidity—No. (%)178 (61.4)158 (63.5)20 (48.8).074
Hypertension81 (27.9)68 (27.3)13 (31.7).561
Diabetes mellitus27 (9.3)25 (10)2 (4.9).393
Coronary heart disease18 (6.2) (6.2)18 (7.2)0 (0.0).087
Drug hypersensitivity (self‐reported)10 (3.4)10 (4.0)0 (0.0).367
COPD6 (2.1)6 (2.4)0 (0.0).600
Urticaria2 (0.7)1 (0.4)1 (2.4).263
Asthma1 (0.3)1 (0.4)0 (0.0)>.999
Others72 (24.8)66 (26.5)6 (14.6).103
Surgery history—No. (%)89 (30.7)82 (32.9)7 (17.1).041
Tumor surgery15 (5.2)15 (6.0)0 (0.0).141
Craniocerebral surgery6 (2.1)6 (2.4)0 (0).600
Cardiac intervention10 (3.4)10 (4.0)0 (0).367
Others62 (21.4)55 (22.1)7 (17.1).468
Smokers—No. (%)28 (9.7)25 (10)3 (7.3).778
Past Smokers18 (6.2)16 (6.4)2 (4.9)>.999
Current Smokers10 (3.4)9 (3.6)1 (2.4)>.999
Severity—No. (%)
Severe121 (41.7)111 (44.6)10 (24.4).015
Nonsevere169 (58.3)138 (55.4)31 (75.6)

COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; rRT‐PCR, real‐time reverse transcription–polymerase chain reaction; COPD, chronic obstructive pulmonary disease; P values denote the statistical significance between initially positive and negative result subgroups.

Demographics and partial clinical data of patients with COVID‐19 COVID‐19, coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; rRT‐PCR, real‐time reverse transcription–polymerase chain reaction; COPD, chronic obstructive pulmonary disease; P values denote the statistical significance between initially positive and negative result subgroups. Compared to patients with an initial negative rRT‐PCR result, patients with an initial positive result were more likely to progress to a severe condition (44.6% vs 24.4%, P = .015) (Table 1). In 226 patients with available chest CT images, 214 (94.7%) had typical patterns of COVID‐19, and the proportions for initially positive and negative patients with abnormal CT images were 94.2% (180/191) and 97.1% (34/35), respectively. On February 28th, out of the 290 patients, 189 (65.2%) were discharged and, unfortunately, 46 (15.9%) did not survive. The mortality of patients with an initial negative rRT‐PCR result [5 (12.2%)] was slightly lower than those with a positive result [41 (16.5%)], whereas the proportion of discharged patients from the negative group [32 (78%)] tended to be larger than the positive group [157 (63.1%)], without any statistically significant difference (Table S1). The laboratory results of patients on admission are shown in Table S2. Among 290 patients, leukopenia (n = 78, 26.9%), neutropenia (n = 51, 17.6%), lymphopenia (n = 203, 70.0%), eosinopenia (n = 171, 59.0%), and thrombocytopenia (n = 65, 22.4%) were observed, without any significant difference between patients with initial positive and negative rRT‐PCR results. Elevated levels of C‐reactive protein (n = 249, 88%), serum amyloid A (n = 149, 84.2%), procalcitonin (n = 85, 31.1%), D‐dimer (n = 105, 45.3%), and serum creatine kinase (n = 30, 15.7%) were found. No significant difference was seen between the initial positive and negative patients within these acute phase reactants (all P > .05) (Table S2). In general, except for two aspects (surgery history and severity), no significant difference was observed in clinical manifestations, laboratory findings, and radiological changes between patients with initial positive and negative rRT‐PCR results in the present study. Similar results were reported by Li et al and Lu et al, , where patients with a positive rRT‐PCR test appeared to have increased disease severity, although the differences were not statistically significant in Li's (35.5% vs 13%, P = .063) and Lu's (20.8% vs 13.7%, P = .20) study. Surgery history may be a confounding factor in this study, which may also relate to factors such as age and sex. The findings of further logistic regression analysis showed no predictive value for the history of surgery. Previous studies suggested that a false‐negative rRT‐PCR result may occur in some COVID‐19 patients. , False‐negative results may occur as a result of various factors, such as human errors when following the diagnostic kit protocol, the sensitivity of reagents, the site and method of specimen sampling and collection times. It should be noted that a fraction of initial rRT‐PCR negative results may be due to low or no virus expression in the sampled area. In regard to the site of specimen sampling, it has been previously reported that the viral load in the nose is higher than in the pharynx, and the virus detection rate in the lower respiratory tract is higher than in the upper respiratory tract. Currently, most samples are collected from the upper respiratory tract, such as oropharynx swabs, due to ease of sampling or absence of sputum in the patient, which may lead to false‐negative rRT‐PCR results. Another important point to emphasize here is that the same errors for initial negative results can occur at the time of decision to discharge for clinically healed patients. As can be seen, the patients involved in the study are all hospitalized cases and we had a chance to further confirm the data with clinical diagnosis and repeated rRT‐PCR tests. Some of the false‐positive results can be because of low virus expression in pharynx samples, which can be even higher percentages in nonhospitalized cases. In this context, the isolation of COVID‐19 suspected patients should be more vigorous and the decision should not only depend on rRT‐PCR positivity during the time of the pandemics. The findings presented herein suggest that a considerable proportion of COVID‐19 patients may have an initial negative rRT‐PCR result and that initially positive patients had a higher tendency to progress to severe cases. Therefore, diagnosis of SARS‐CoV‐2 infection should not be excluded in patients with an initial negative rRT‐PCR result, especially when presented with typical clinical manifestations. In view of these results, we recommend repeated rRT‐PCR tests to confirm diagnosis and identify potentially infected individuals.

CONFLICT OF INTEREST

The authors have no conflict of interest. Sup info Click here for additional data file.
  6 in total

1.  Quantification of mRNA using real-time RT-PCR.

Authors:  Tania Nolan; Rebecca E Hands; Stephen A Bustin
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

2.  Detection of SARS-CoV-2 in Different Types of Clinical Specimens.

Authors:  Wenling Wang; Yanli Xu; Ruqin Gao; Roujian Lu; Kai Han; Guizhen Wu; Wenjie Tan
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

3.  [Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with coronavirus disease 2019].

Authors:  Y Y Li; W N Wang; Y Lei; B Zhang; J Yang; J W Hu; Y L Ren; Q F Lu
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2020-05-12

4.  Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion.

Authors:  Peikai Huang; Tianzhu Liu; Lesheng Huang; Hailong Liu; Ming Lei; Wangdong Xu; Xiaolu Hu; Jun Chen; Bo Liu
Journal:  Radiology       Date:  2020-02-12       Impact factor: 11.105

5.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.

Authors:  J S M Peiris; C M Chu; V C C Cheng; K S Chan; I F N Hung; L L M Poon; K I Law; B S F Tang; T Y W Hon; C S Chan; K H Chan; J S C Ng; B J Zheng; W L Ng; R W M Lai; Y Guan; K Y Yuen
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

6.  Chest CT for Typical Coronavirus Disease 2019 (COVID-19) Pneumonia: Relationship to Negative RT-PCR Testing.

Authors:  Xingzhi Xie; Zheng Zhong; Wei Zhao; Chao Zheng; Fei Wang; Jun Liu
Journal:  Radiology       Date:  2020-02-12       Impact factor: 11.105

  6 in total
  33 in total

Review 1.  COVID-19 Pandemic and the Global Perspective of Turkish Thoracic Society.

Authors:  Nurdan Köktürk; Bahriye Oya İtil; Göksel Altınışık; Nalan Adıgüzel; Metin Akgün; Levent Akyıldız; Sedat Altın; Hüseyin Arıkan; Güngör Ateş; Pınar Ay; Nilüfer Aykaç; Cenk Babayiğit; Pınar Bostan; Güzin Cinel; Haluk Celaleddin Çalışır; Pınar Çelik; Pelin Duru Çetinkaya; Elif Dağlı; Ahmet Uğur Demir; Canan Demir; Öner Dikensoy; Ebru Çakır Edis; Osman Elbek; Münevver Erdinç; Begüm Ergan; A Füsun Öner Eyüboğlu; Bilun Gemicioğlu; Tuncay Göksel; Erkmen Gülhan; Ökkeş Gültekin; Canan Gündüz Gürkan; Alev Gürgün; Yavuz Havlucu; Ozen K Başoğlu; Sait Karakurt; Zuhal Karakurt; Oğuz Kılınç; Ali Kocabaş; Seval Kul; Benan Müsellim; Sibel Naycı; Metin Özkan; Özgün Pınarer; Cüneyt Saltürk; Abdulsamet Sandal; Abdullah Sayıner; Elif Şen; Gökçen Ömeroğlu Şimşek; Bülent Taner Karadağ; Fatma Tokgöz Akyıl; Zehra Nur Töreyin; Eyüp Sabri Uçan; Filiz Çağla Uyanusta Küçük; Ayhan Varol; Yeşim Yasin; Tekin Yıldız; A Arzu Yorgancıoğlu; Hasan Bayram
Journal:  Turk Thorac J       Date:  2020-11-01

2.  Comparison of clinical characteristics and outcome in RT-PCR positive and false-negative RT-PCR for COVID-19: A Retrospective analysis.

Authors:  Durga Shankar Meena; Bharat Kumar; Arjun Kachhwaha; Deepak Kumar; Satyendra Khichar; Gopal Krishana Bohra; Ankur Sharma; Nikhil Kothari; Pawan Garg; Binit Sureka; Mithu Banerjee; Mahendra Kumar Garg; Sanjeev Misra
Journal:  Infez Med       Date:  2022-09-01

Review 3.  A compendium answering 150 questions on COVID-19 and SARS-CoV-2.

Authors:  Carmen Riggioni; Pasquale Comberiati; Mattia Giovannini; Ioana Agache; Mübeccel Akdis; Magna Alves-Correia; Josep M Antó; Alessandra Arcolaci; Ahmet Kursat Azkur; Dilek Azkur; Burcin Beken; Cristina Boccabella; Jean Bousquet; Heimo Breiteneder; Daniela Carvalho; Leticia De Las Vecillas; Zuzana Diamant; Ibon Eguiluz-Gracia; Thomas Eiwegger; Stefanie Eyerich; Wytske Fokkens; Ya-Dong Gao; Farah Hannachi; Sebastian L Johnston; Marek Jutel; Aspasia Karavelia; Ludger Klimek; Beatriz Moya; Kari C Nadeau; Robyn O'Hehir; Liam O'Mahony; Oliver Pfaar; Marek Sanak; Jürgen Schwarze; Milena Sokolowska; María J Torres; Willem van de Veen; Menno C van Zelm; De Yun Wang; Luo Zhang; Rodrigo Jiménez-Saiz; Cezmi A Akdis
Journal:  Allergy       Date:  2020-07-20       Impact factor: 14.710

4.  Asthma and COVID-19 in children - a systematic review and call for data.

Authors:  Jose A Castro-Rodriguez; Erick Forno
Journal:  medRxiv       Date:  2020-05-08

5.  [Asthma and COVID-19: a risk population?]

Authors:  M Underner; G Peiffer; J Perriot; N Jaafari
Journal:  Rev Mal Respir       Date:  2020-05-15       Impact factor: 0.622

6.  Asthma and COVID-19 in children: A systematic review and call for data.

Authors:  Jose A Castro-Rodriguez; Erick Forno
Journal:  Pediatr Pulmonol       Date:  2020-07-06

7.  ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020).

Authors:  Jean Bousquet; Marek Jutel; Cezmi A Akdis; Ludger Klimek; Oliver Pfaar; Kari C Nadeau; Thomas Eiwegger; Anna Bedbrook; Ignacio J Ansotegui; Josep M Anto; Claus Bachert; Eric D Bateman; Kazi S Bennoor; Elena Camelia Berghea; Karl-Christian Bergmann; Hubert Blain; Mateo Bonini; Sinthia Bosnic-Anticevich; Louis-Philippe Boulet; Luisa Brussino; Roland Buhl; Paulo Camargos; Giorgio Walter Canonica; Victoria Cardona; Thomas Casale; Sharon Chinthrajah; Mübeccel Akdis; Tomas Chivato; George Christoff; Alvaro A Cruz; Wienczyslawa Czarlewski; Stefano Del Giacco; Hui Du; Yehia El-Gamal; Wytske J Fokkens; Joao A Fonseca; Yadong Gao; Mina Gaga; Bilun Gemicioglu; Maia Gotua; Tari Haahtela; David Halpin; Eckard Hamelmann; Karin Hoffmann-Sommergruber; Marc Humbert; Nataliya Ilina; Juan-Carlos Ivancevich; Guy Joos; Musa Khaitov; Bruce Kirenga; Edward F Knol; Fanny W Ko; Seppo Koskinen; Marek L Kowalski; Helga Kraxner; Dmitry Kudlay; Piotr Kuna; Maciej Kupczyk; Violeta Kvedariene; Amir H Abdul Latiff; Lan T Le; Michael Levin; Desiree Larenas-Linnemann; Renaud Louis; Mohammad R Masjedi; Erik Melén; Florin Mihaltan; Branislava Milenkovic; Yousser Mohammad; Mario Morais-Almeida; Joaquim Mullol; Leyla Namazova; Hugo Neffen; Elisabete Nunes; Paul O'Byrne; Robyn O'Hehir; Liam O'Mahony; Ken Ohta; Yoshitaka Okamoto; Gabrielle L Onorato; Petr Panzner; Nikos G Papadopoulos; Gianni Passalacqua; Vincenzo Patella; Ruby Pawankar; Nhân Pham-Thi; Bernard Pigearias; Todor A Popov; Francesca Puggioni; Frederico S Regateiro; Giovanni Rolla; Menachem Rottem; Boleslaw Samolinski; Joaquin Sastre; Jurgen Schwarze; Aziz Sheikh; Nicola Scichilone; Manuel Soto-Quiros; Manuel Soto-Martinez; Milan Sova; Stefania Nicola; Rafael Stelmach; Charlotte Suppli-Ulrik; Luis Taborda-Barata; Teresa To; Peter-Valentin Tomazic; Sanna Toppila-Salmi; Ioanna Tsiligianni; Omar Usmani; Arunas Valiulis; Maria Teresa Ventura; Giovanni Viegi; Theodor Vontetsianos; De Yun Wang; Sian Williams; Gary W K Wong; Arzu Yorgancioglu; Mario Zernotti; Mihaela Zidarn; Torsten Zuberbier; Ioana Agache
Journal:  Allergy       Date:  2020-09-21       Impact factor: 14.710

8.  COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients.

Authors:  Oliver Pfaar; Maria J Torres; Cezmi A Akdis
Journal:  Allergy       Date:  2021-03       Impact factor: 14.710

Review 9.  Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases.

Authors:  Christopher R Carpenter; Philip A Mudd; Colin P West; Erin Wilber; Scott T Wilber
Journal:  Acad Emerg Med       Date:  2020-07-26       Impact factor: 5.221

10.  COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper.

Authors:  Oliver Pfaar; Ludger Klimek; Marek Jutel; Cezmi A Akdis; Jean Bousquet; Heimo Breiteneder; Sharon Chinthrajah; Zuzana Diamant; Thomas Eiwegger; Wytske J Fokkens; Hans-Walter Fritsch; Kari C Nadeau; Robyn E O'Hehir; Liam O'Mahony; Winfried Rief; Vanitha Sampath; Manfred Schedlowski; María José Torres; Claudia Traidl-Hoffmann; De Yun Wang; Luo Zhang; Matteo Bonini; Randolf Brehler; Helen Annaruth Brough; Tomás Chivato; Stefano R Del Giacco; Stephanie Dramburg; Radoslaw Gawlik; Aslı Gelincik; Karin Hoffmann-Sommergruber; Valerie Hox; Edward F Knol; Antti Lauerma; Paolo M Matricardi; Charlotte G Mortz; Markus Ollert; Oscar Palomares; Carmen Riggioni; Jürgen Schwarze; Isabel Skypala; Eva Untersmayr; Jolanta Walusiak-Skorupa; Ignacio J Ansotegui; Claus Bachert; Anna Bedbrook; Sinthia Bosnic-Anticevich; Luisa Brussino; Giorgio Walter Canonica; Victoria Cardona; Pedro Carreiro-Martins; Alvaro A Cruz; Wienczyslawa Czarlewski; João A Fonseca; Maia Gotua; Tari Haahtela; Juan Carlos Ivancevich; Piotr Kuna; Violeta Kvedariene; Désirée Erlinda Larenas-Linnemann; Amir Hamzah Abdul Latiff; Mika Mäkelä; Mário Morais-Almeida; Joaquim Mullol; Robert Naclerio; Ken Ohta; Yoshitaka Okamoto; Gabrielle L Onorato; Nikolaos G Papadopoulos; Vincenzo Patella; Frederico S Regateiro; Bolesław Samoliński; Charlotte Suppli Ulrik; Sanna Toppila-Salmi; Arunas Valiulis; Maria-Teresa Ventura; Arzu Yorgancioglu; Torsten Zuberbier; Ioana Agache
Journal:  Allergy       Date:  2021-03       Impact factor: 14.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.